WO2009088256A3 - 배큘로바이러스-기반 백신 - Google Patents

배큘로바이러스-기반 백신 Download PDF

Info

Publication number
WO2009088256A3
WO2009088256A3 PCT/KR2009/000136 KR2009000136W WO2009088256A3 WO 2009088256 A3 WO2009088256 A3 WO 2009088256A3 KR 2009000136 W KR2009000136 W KR 2009000136W WO 2009088256 A3 WO2009088256 A3 WO 2009088256A3
Authority
WO
WIPO (PCT)
Prior art keywords
recombinant baculovirus
operatively connected
nucleotide sequence
baculovirus
antigenic protein
Prior art date
Application number
PCT/KR2009/000136
Other languages
English (en)
French (fr)
Other versions
WO2009088256A9 (ko
WO2009088256A8 (ko
WO2009088256A2 (ko
Inventor
김영봉
이희정
박누리
오유경
Original Assignee
건국대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 건국대학교 산학협력단 filed Critical 건국대학교 산학협력단
Priority to BRPI0906946-1A priority Critical patent/BRPI0906946A2/pt
Priority to EP09700761.1A priority patent/EP2241626B1/en
Priority to JP2010542174A priority patent/JP5309159B2/ja
Priority to CN2009801019712A priority patent/CN101952436B/zh
Priority to US12/812,053 priority patent/US20100285056A1/en
Publication of WO2009088256A2 publication Critical patent/WO2009088256A2/ko
Publication of WO2009088256A3 publication Critical patent/WO2009088256A3/ko
Publication of WO2009088256A8 publication Critical patent/WO2009088256A8/ko
Publication of WO2009088256A9 publication Critical patent/WO2009088256A9/ko
Priority to US14/447,341 priority patent/US9555091B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/866—Baculoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 (a) 바이러스의 외래 엔벨로프 단백질을 코딩하는 뉴클레오타이드 서열; (b) 상기 엔벨로프-코딩 서열에 작동적으로 연결된 제1프로모터; (c) 항원 단백질을 코딩하는 뉴클레오타이드 서열; 및 (d) 상기 항원-코딩 서열에 작동적으로 연결된 제2프로모터를 포함하는 재조합 배큘로바이러스; 상기 재조합 배큘로바이러스를 포함하는 백신 조성물에 관한 것이다. 본 발명의 재조합 배큘로바이러스는 특정 항원(예컨대, HPV의 L1)에 대한 체액성 면역 유도능이 우수할 뿐만 아니라, 세포성 면역 유도능도 우수하여 향상된 백신 효능을 발휘할 수 있다.
PCT/KR2009/000136 2008-01-09 2009-01-09 배큘로바이러스-기반 백신 WO2009088256A2 (ko)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BRPI0906946-1A BRPI0906946A2 (pt) 2008-01-09 2009-01-09 Vacinas baseadas em baculovírus
EP09700761.1A EP2241626B1 (en) 2008-01-09 2009-01-09 Baculovirus-based vaccines
JP2010542174A JP5309159B2 (ja) 2008-01-09 2009-01-09 バキュロウイルスを利用したワクチン
CN2009801019712A CN101952436B (zh) 2008-01-09 2009-01-09 基于杆状病毒的疫苗
US12/812,053 US20100285056A1 (en) 2008-01-09 2009-01-09 Baculovirus-Based Vaccines
US14/447,341 US9555091B2 (en) 2008-01-09 2014-07-30 Baculovirus-based vaccines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20080002733 2008-01-09
KR10-2008-0002733 2008-01-09

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/812,053 A-371-Of-International US20100285056A1 (en) 2008-01-09 2009-01-09 Baculovirus-Based Vaccines
US14/447,341 Division US9555091B2 (en) 2008-01-09 2014-07-30 Baculovirus-based vaccines

Publications (4)

Publication Number Publication Date
WO2009088256A2 WO2009088256A2 (ko) 2009-07-16
WO2009088256A3 true WO2009088256A3 (ko) 2009-10-08
WO2009088256A8 WO2009088256A8 (ko) 2010-03-25
WO2009088256A9 WO2009088256A9 (ko) 2012-07-12

Family

ID=40853624

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/000136 WO2009088256A2 (ko) 2008-01-09 2009-01-09 배큘로바이러스-기반 백신

Country Status (7)

Country Link
US (2) US20100285056A1 (ko)
EP (1) EP2241626B1 (ko)
JP (1) JP5309159B2 (ko)
KR (2) KR101164602B1 (ko)
CN (1) CN101952436B (ko)
BR (1) BRPI0906946A2 (ko)
WO (1) WO2009088256A2 (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8821477B2 (en) 2007-08-06 2014-09-02 Boston Scientific Scimed, Inc. Alternative micromachined structures
WO2011160848A1 (en) * 2010-06-23 2011-12-29 Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechtes Rearranged tt virus molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity
PT2861604T (pt) 2012-06-08 2017-05-05 Gilead Sciences Inc Inibidores macrocíclicos de vírus flaviridae
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
IN2014MN02658A (ko) 2012-06-08 2015-08-21 Gilead Sciences Inc
KR102138938B1 (ko) * 2018-01-19 2020-07-29 건국대학교 산학협력단 인플루엔자 유래 세포 침투성 펩타이드를 포함하는 배큘로바이러스 기반 유전자 전달체
CN113164623A (zh) 2018-09-18 2021-07-23 维恩维纽克公司 基于arc的衣壳及其用途
CN110343722A (zh) * 2019-07-03 2019-10-18 上海大学 一种重组表达水痘-带状疱疹病毒v-Oka株截短型糖蛋白E的方法
US11129892B1 (en) 2020-05-18 2021-09-28 Vnv Newco Inc. Vaccine compositions comprising endogenous Gag polypeptides
CN113150086B (zh) * 2021-04-22 2022-10-11 成都欧林生物科技股份有限公司 幽门螺杆菌HefC重组蛋白及其应用
CN113514440A (zh) * 2021-07-01 2021-10-19 广州博徕斯生物科技股份有限公司 杆状病毒荧光纳米探针

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0265785A2 (en) * 1986-10-16 1988-05-04 Microgenesys, Inc. Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells
WO1992002548A1 (fr) * 1990-08-10 1992-02-20 Institut Pasteur Baculovirus recombinant exprimant les proteins e et nsi de virus appartenant aux flaviviridae ou de virus apparentes aux flaviviridae

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
GB8810808D0 (en) 1988-05-06 1988-06-08 Wellcome Found Vectors
US5169784A (en) * 1990-09-17 1992-12-08 The Texas A & M University System Baculovirus dual promoter expression vector
US5352775A (en) 1991-01-16 1994-10-04 The Johns Hopkins Univ. APC gene and nucleic acid probes derived therefrom
DK0595935T3 (da) * 1991-07-19 2003-07-21 Csl Ltd Papillomavirusvaccine
CA2113990A1 (en) 1991-07-26 1993-02-18 Frederick L. Moolten Cancer therapy utilizing malignant cells
ATE261314T1 (de) 1992-07-22 2004-03-15 Univ Princeton P53 impfstoff
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
FR2732357B1 (fr) 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
FR2740344B1 (fr) 1995-10-31 1997-11-21 Rhone Poulenc Rorer Sa Application de la proteine gax au traitement de cancers
US5858723A (en) * 1995-12-05 1999-01-12 Behringwerke Aktiengesellschaft Polypeptides and antibodies for diagnosing and treating seminoma
US6077662A (en) 1996-11-27 2000-06-20 Emory University Virus-like particles, methods and immunogenic compositions
EP0980257A1 (en) * 1997-05-01 2000-02-23 Chiron Corporation Use of virus-like particles as adjuvants
GB9711578D0 (en) * 1997-06-04 1997-07-30 Oxford Biomedica Ltd Novel retroviral vector production systems
FR2797889A1 (fr) * 1999-09-01 2001-03-02 Bio Merieux Procede de detection de l'expression d'une proteine d'enveloppe d'un retrovirus endogene humain et utilisations d'un gene codant pour cette proteine
AU2003219760A1 (en) 2002-02-14 2003-09-04 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
CN101007168B (zh) * 2006-01-23 2010-06-09 北京大学 一种sars疫苗及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0265785A2 (en) * 1986-10-16 1988-05-04 Microgenesys, Inc. Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells
WO1992002548A1 (fr) * 1990-08-10 1992-02-20 Institut Pasteur Baculovirus recombinant exprimant les proteins e et nsi de virus appartenant aux flaviviridae ou de virus apparentes aux flaviviridae

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 11 May 1999 (1999-05-11), XP008137530, Database accession no. AF072506.2 *
See also references of EP2241626A4 *
SHENGPING WANG ET AL.: "Construction and immunogenicity of pseudotype baculovirus expressing GP5 and M protein of porcine reproductive and respiratory syndrome virus", VACCINE, vol. 25, 22 October 2007 (2007-10-22), pages 8220 - 8227, XP022343186 *
STEPHEN J. JARRIS ET AL.: "Hybrid Human Immunodeficiency Virus Gag Particles as an Antigen Carrier System: Induction of cytotoxic T-cell and Humoral Responses by a Gag:V3 Fusion", J. VIROLOGY, vol. 67, no. 6, June 1993 (1993-06-01), pages 3191 - 3198, XP008137529 *

Also Published As

Publication number Publication date
KR101164602B1 (ko) 2012-07-10
KR20090076852A (ko) 2009-07-13
BRPI0906946A2 (pt) 2015-07-14
US20150030621A1 (en) 2015-01-29
EP2241626A2 (en) 2010-10-20
CN101952436A (zh) 2011-01-19
EP2241626A4 (en) 2013-01-23
EP2241626B1 (en) 2016-01-06
WO2009088256A9 (ko) 2012-07-12
JP2011509092A (ja) 2011-03-24
WO2009088256A8 (ko) 2010-03-25
US20100285056A1 (en) 2010-11-11
WO2009088256A2 (ko) 2009-07-16
KR20110052552A (ko) 2011-05-18
US9555091B2 (en) 2017-01-31
JP5309159B2 (ja) 2013-10-09
CN101952436B (zh) 2013-03-13

Similar Documents

Publication Publication Date Title
WO2009088256A8 (ko) 배큘로바이러스-기반 백신
WO2020193688A3 (en) Immunogenic compositions and vaccines comprising african swine fever virus peptides and proteins and uses thereof
WO2008148104A8 (en) Novel vlps derived from cells that do not express a viral matrix or core protein
WO2006020071A3 (en) Vaccines against aids comprising cmv/r-nucleic acid constructs
WO2008145401A3 (en) Mutated parvovirus structural proteins as vaccines
WO2010115133A8 (en) Newcastle disease virus vectored avian vaccines
MX2009009342A (es) Metodo novedoso y composiciones.
WO2011054011A3 (en) Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
WO2004001051A3 (en) Recombinant measles viruses expressing epitopes pf antigens of rna viruses and use of the recombinant viruses for the preparation of vaccine compositions
WO2010118424A3 (en) Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines
GB2434367A (en) Improved vaccines
MX346245B (es) Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria.
UA108081C2 (uk) Модифікація рекомбінантного аденовірусу імуногенними епітопами білка circumsporozoite плазмодія
WO2014150822A3 (en) Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
WO2007016598A3 (en) Influenza vaccine compositions and methods of use thereof
WO2010001409A3 (en) Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same
WO2011146933A3 (en) Universal dengue virus sequences and methods of use
MX2013005205A (es) Virus del sindrome reproductivo y respiratorio porcino (prrs) de los estados unidos y sus usos.
WO2012018907A3 (en) Polypeptides for treating and/or limiting influenza infection
AU2018388102A1 (en) Cross-immunizing antigen vaccine and method for preparation thereof
MY197457A (en) Chimeric papillomavirus l1 protein
WO2010040847A3 (en) Recombinant protein bodies as immunogen-specific adjuvants
WO2007082734A3 (en) Influenza vaccine
MX2013000787A (es) Vectores de parapoxvirus.
NZ599219A (en) Adjuvanted vaccine formulations

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980101971.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09700761

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009700761

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010542174

Country of ref document: JP

Ref document number: 12812053

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1694/MUMNP/2010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: PI0906946

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100708